Ensign Peak Advisors Inc Purchases Shares of 65,550 ADMA Biologics, Inc. (NASDAQ:ADMA)

Ensign Peak Advisors Inc bought a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 65,550 shares of the biotechnology company's stock, valued at approximately $1,124,000.

A number of other large investors also recently bought and sold shares of ADMA. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in ADMA Biologics by 1.3% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock valued at $865,000 after acquiring an additional 645 shares during the period. Oregon Public Employees Retirement Fund boosted its position in ADMA Biologics by 1.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock valued at $954,000 after purchasing an additional 700 shares during the period. Summit Investment Advisors Inc. grew its stake in ADMA Biologics by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company's stock worth $404,000 after buying an additional 746 shares during the last quarter. Mutual of America Capital Management LLC increased its position in ADMA Biologics by 2.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock worth $614,000 after buying an additional 751 shares during the period. Finally, Maryland State Retirement & Pension System lifted its stake in ADMA Biologics by 1.1% in the fourth quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company's stock valued at $1,365,000 after buying an additional 897 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Performance

Shares of ADMA traded up $0.25 during trading hours on Tuesday, reaching $20.44. 2,452,733 shares of the company's stock traded hands, compared to its average volume of 3,708,471. The firm has a market capitalization of $4.88 billion, a price-to-earnings ratio of 73.00 and a beta of 0.57. The business's fifty day simple moving average is $20.52 and its two-hundred day simple moving average is $18.88. ADMA Biologics, Inc. has a twelve month low of $9.22 and a twelve month high of $25.67. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. During the same period in the prior year, the company posted $0.08 earnings per share. The company's revenue was up 40.2% on a year-over-year basis. Analysts predict that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on ADMA. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th. StockNews.com lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Finally, Raymond James raised their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $24.25.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.